BNTX

BioNTech SE

NasdaqGSUSDEQUITY DELAYED

116.71

▲ 5.82 (5.25%)

MARKET · —

Price

Open

111.12

Prev close

110.89

Day high

120.30

Day low

110.89

Volume

2.96M

Market cap

—

P/E (TTM)

—

52W range

79.52 – 124.00

Trailing performance

Price return · vs SPY

Returnvs SPY

+25.22% +26.6%

+26.62% +22.9%

+28.20% +25.1%

+5.83% -5.2%

YTD

+22.45% +10.2%

+4.73% -15.3%

+7.98% -66.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

98.85

+18.07% from price

SMA 20

95.45

+22.12% from price

SMA 50

93.26

+25.00% from price

SMA 100

94.03

+24.11% from price

SMA 200

97.58

+19.46% from price

EMA 12

100.79

+15.80% from price

EMA 26

96.61

+20.81% from price

EMA 50

94.75

+23.18% from price

RSI (14)

79.2

Overbought

MACD (12,26,9)

4.18

Hist 2.57

ATR (14)

4.79

4.11% of price

Realised vol 30D

61.6%

Annualised

Bollinger upper

110.82

20, 2σ

Bollinger lower

80.09

20, 2σ

50 / 200 cross

Death

93.26 vs 97.58

Trend bias

Above 200

+19.46%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.87

Less volatile than market

Correlation to SPY

0.24

Largely independent

Realised vol 30D

61.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-29.7%

Peak to trough

Max drawdown 5Y

-79.5%

Peak to trough

ATR 14

4.79

4.11% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 116.71

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

BNTX · links out to the publisher

Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players Barrons.com · 20h ago European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading MT Newswires · 1d ago Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session 24/7 Wall St. · 1d ago Moderna And Merck's Cancer Vaccine: Are Investors Putting The Cart Before The Horse? Investor's Business Daily · 2d ago Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips 24/7 Wall St. · 2d ago European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT Newswires · 2d ago BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade. Barrons.com · 2d ago Moderna’s Personalized Cancer Vaccine Proves Its mRNA Tech Works. A $3 Billion Market Awaits. Barrons.com · 2d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.